Mark your calendars for Wednesday 30th October 2024, as NovoCure Limited (NASDAQ: NVCR) will be revealing its third quarter financial results. This highly awaited announcement is scheduled to take place before market open, pave the way to review a period of expectation and anticipation.
Financial analysts on Wall Street are predicting that the concern is expected to report an estimated per share $0.33 loss for the current quarter. Additionally, the company is anticipated to reveal a total revenue of $143.95 million during this period.
Financial experts on Wall Street have shared their predictions regarding the company's annual performance, estimating a total revenue of $580.56 million. Additionally, they are expecting the company to report loss of $1.35 per share for the full year 2024.
In the same quarter of the previous year, the company's financial statement revealed a per-share loss of $0.46. Additionally, the company's overall revenue for that particular period was an impressive $127.32 million.
| Period | EPS Actual |
EPS Growth* |
Revenue Actual |
Revenue Growth* |
|---|---|---|---|---|
| Historical Earnings Insight | ||||
| Q2 2024 | $-0.31 | +42.6% | 150.36 M | +19.3% |
| Q1 2024 | $-0.36 | +28.0% | 138.50 M | +13.4% |
| Q4 2023 | $-0.45 | -25.0% | 133.78 M | +4.2% |
| Q3 2023 | $-0.46 | -84.0% | 127.32 M | -2.8% |
| Q2 2023 | $-0.54 | -134.8% | 126.05 M | -10.5% |
| *Growth on year-over-year basis | ||||
In addition, The firm will review the third quarter financial results on 30th October 2024 at 08:00 AM eastern time, in a conference call with public.
NovoCure Limited (NVCR) shares experienced a range of $16.51 to $17.31 on a day volume of 1.07 million shares. The stock closed Monday's regular trading session at $16.62, marking a 0.72 percent decline.
